Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 1

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 1
---
──────────────────────────────────────────────────────────────────────

1

  Clinical trials involve a lengthy and expensive process with an uncertain outcome,        
  and results of earlier studies and trials may not be predictive of future trial results.  
 ────────────────────────────────────────────────────────────────────────────────────────────

  Even if we obtain regulatory approvals, our therapeutic candidates will be subject                                                             

  We generally rely on third parties to conduct our preclinical studies and clinical                                                      
  trials and to provide other services, and those third parties may not perform satisfactorily, including by failing to meet established  
  deadlines for the completion of such services.                                                                                          
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  We recently entered into and may in the future rely on out-licensing arrangements          
  for late-stage development, marketing or commercialization of our therapeutic candidates.  
 ─────────────────────────────────────────────────────────────────────────────────────────────

  If we cannot meet requirements under our in-license agreements, we could lose the                  

  We have partnered with and may seek to partner with third-party collaborators with                                                         
  respect to the development and commercialization of motixafortide, and we may not succeed in establishing and maintaining collaborative    
  relationships, which may significantly limit our ability to develop and commercialize our therapeutic candidates successfully, if at all.  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  If competitors develop and market therapeutics that are more effective, safer or less                    

  APHEXDA, or any other therapeutic candidate that we or our licensees are able to commercialize,                                         
  may become subject to unfavorable pricing regulations, third-party payor reimbursement practices or healthcare reform initiatives, any  
  of which could harm our business.                                                                                                       
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  We rely upon third-party manufacturers to produce therapeutic supplies for the clinical                                                          

Risks Related to Our Industry

  Healthcare reforms and related reductions in pharmaceutical pricing, reimbursement and coverage by government  
  authorities and third-party payors may adversely affect our business.                                          
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  If third-party payors do not adequately reimburse customers for any of our therapeutic candidates that                       

  Our business has a substantial risk of clinical trial and product liability claims. If we